Earlier this month, the National Screening Committee (NSC) recommended against population-level prostate cancer screening in the UK, recommending screening only for a very select few men with known BRCA2 mutations and a family history of prostate, breast, ovarian, or pancreatic cancer.

TRANSFORM aims to fill the evidence gap identified by the NSC and provide definitive answers on the best way to screen for prostate cancer.